RobertCKupperTS. Inflammatory skin diseases, T-cells, and immune surveillance. N Engl J Med1999; 341:1817–1828.
2.
PrinzJC. The role of T-cells in psoriasis. J Eur Acad Dermatol Venereol2003; 17:257–270.
3.
HittELieD. Biologic agents show efficacy in patients with plaque psoriasis. Medscape Medical Views2003; www.medscape.com/viewarticle/464696.
4.
MrowietzU. Advances in systemic therapy for psoriasis. Clin Exp Dermatol2001; 26:362–367.
5.
KruegerJG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol2002; 46:1–23.
6.
EllisCNKruegerGG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med2001; 345:248–255.
7.
BosJDHagenaarsCDasPK. Predominance of ‘memory’ T-cells (CD4+, CDw29+) over ‘naïve’ T-cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res1989; 281:24–30.
8.
MorganrothGSChanLSWeinsteinGD. Proliferating cells in psoriatic dermis are comprised primarily of T-cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol1991; 96:333–340.
9.
KruegerGGCallisKP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol2003; 49:S87–S97.
10.
MehlisSLGordonKB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol2003; 49:S44–S50.
11.
Van den BrandeJMBraatHvan den BrinkGR. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology2003; 124:1774–1785.
